Akebia Therapeutics reported $55.18M in Sales Revenues for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Akebia Therapeutics AKBA:US USD 55.18M 6.22M
Amgen AMGN:US USD 6.84B 187M
Astellas Pharma 4503:JP JPY 402.18B 21.79B
AstraZeneca AZN:LN USD 11.21B 225M
Exelixis EXEL:US USD 423.92M 12.18M
GlaxoSmithKline GSK:LN GBP 7.38B 453M
Johnson & Johnson JNJ:US USD 23.71B 85M
Karyopharm Therapeutics KPTI:US USD 33.58M 2.56M
Opko Health OPK:US USD 185.4M 5.66M
Regeneron Pharmaceuticals REGN:US USD 3.41B 478.2M
Seattle Genetics SGEN:US USD 528.15M 17.85M